2016
Adjuvant Chemotherapy for T3 Non–Small Cell Lung Cancer with Additional Tumor Nodules in the Same Lobe
Salazar MC, Rosen JE, Arnold BN, Thomas DC, Kim AW, Detterbeck FC, Blasberg JD, Boffa DJ. Adjuvant Chemotherapy for T3 Non–Small Cell Lung Cancer with Additional Tumor Nodules in the Same Lobe. Journal Of Thoracic Oncology 2016, 11: 1090-1100. PMID: 27013407, DOI: 10.1016/j.jtho.2016.03.009.Peer-Reviewed Original ResearchConceptsAdditional tumor nodulesAdjuvant chemotherapyT3 tumorsSame lobeTumor nodulesPostoperative chemotherapyOverall survivalSurgical resectionSurvival advantageNon-small cell lung cancerNational Cancer Data BaseNon-small cell lungAdditional pulmonary nodulesAdjuvant chemotherapy subgroupSurvival of patientsCell lung cancerSeparate tumor nodulesChemotherapy subgroupPrimary outcomeCell lungLung cancerChemotherapyCox modelRelative survivalPatients
2015
Gender, Age, and Comorbidity Status Predict Improved Survival with Adjuvant Chemotherapy Following Lobectomy for Non-small Cell Lung Cancers Larger than 4 cm
Sandler BJ, Wang Z, Hancock JG, Boffa DJ, Detterbeck FC, Kim AW. Gender, Age, and Comorbidity Status Predict Improved Survival with Adjuvant Chemotherapy Following Lobectomy for Non-small Cell Lung Cancers Larger than 4 cm. Annals Of Surgical Oncology 2015, 23: 638-645. PMID: 26474557, DOI: 10.1245/s10434-015-4902-8.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAge FactorsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellChemotherapy, AdjuvantCohort StudiesCombined Modality TherapyComorbidityFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedNeoplasm StagingPneumonectomyPrognosisSex FactorsSurvival RateYoung AdultConceptsNon-small cell lung cancerAdjuvant chemotherapyNational Cancer Data BaseNon-small cell lungCharlson-Deyo scorePretreatment prognostic factorsCell lung cancerCD scoresGroup of womenGroup of menConclusionsAdjuvant chemotherapySurvival benefitT2 tumorsPrognostic factorsDistant metastasisWomen 65Cell lungLung cancerNSCLC tumorsImproved outcomesChemotherapySurgeryPatientsWomenSurvival
2014
Now or Later: Evaluating the Importance of Chemotherapy Timing in Resectable Stage III (N2) Lung Cancer in the National Cancer Database
Boffa DJ, Hancock JG, Yao X, Goldberg S, Rosen JE, Kim AW, Moreno A, Detterbeck FC. Now or Later: Evaluating the Importance of Chemotherapy Timing in Resectable Stage III (N2) Lung Cancer in the National Cancer Database. The Annals Of Thoracic Surgery 2014, 99: 200-208. PMID: 25440272, DOI: 10.1016/j.athoracsur.2014.08.040.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerNational Cancer DatabaseStage III non-small cell lung cancerPreoperative chemotherapyPostoperative chemotherapyLung cancerCancer DatabaseIII-N2 non-small cell lung cancerStage III lung cancerStage III NSCLC patientsTiming of chemotherapyCell lung cancerCox proportional hazardsSeparate Cox modelsNSCLC patientsChemotherapy resultsChemotherapy timingAdjusted comparisonsChemotherapy approachesChemotherapyCox modelProportional hazardsPatientsTumor attributesCStageA Practical Guide from the International Thymic Malignancy Interest Group (ITMIG) Regarding the Radiographic Assessment of Treatment Response of Thymic Epithelial Tumors Using Modified RECIST Criteria
Benveniste MF, Korst RJ, Rajan A, Detterbeck FC, Marom EM. A Practical Guide from the International Thymic Malignancy Interest Group (ITMIG) Regarding the Radiographic Assessment of Treatment Response of Thymic Epithelial Tumors Using Modified RECIST Criteria. Journal Of Thoracic Oncology 2014, 9: s119-s124. PMID: 25396308, DOI: 10.1097/jto.0000000000000296.Peer-Reviewed Original ResearchConceptsInternational Thymic Malignancy Interest GroupTumor measurementsProgression-free survivalThymic epithelial tumorsStandard outcome measuresMulti-institutional studyAccurate tumor measurementsRECIST criteriaTumor responseClinical trialsRadiographic assessmentTreatment responseEpithelial tumorsOutcome measuresResponse rateInterobserver variabilityThymomaPractical guideInterest group recommendationsChemotherapyPleuraTumors
2011
Pushing Forward Into the Darkness, Leaping, and Landing Securely Prognostication and Adjuvant Chemotherapy for Lung Cancer
Detterbeck FC. Pushing Forward Into the Darkness, Leaping, and Landing Securely Prognostication and Adjuvant Chemotherapy for Lung Cancer. CHEST Journal 2011, 140: 1398-1400. PMID: 22147814, DOI: 10.1378/chest.11-1988.Peer-Reviewed Original Research
2004
Systematic Review Evaluating the Timing of Thoracic Radiation Therapy in Combined Modality Therapy for Limited-Stage Small-Cell Lung Cancer
Fried DB, Morris DE, Poole C, Rosenman JG, Halle JS, Detterbeck FC, Hensing TA, Socinski MA. Systematic Review Evaluating the Timing of Thoracic Radiation Therapy in Combined Modality Therapy for Limited-Stage Small-Cell Lung Cancer. Journal Of Clinical Oncology 2004, 22: 4837-4845. PMID: 15570087, DOI: 10.1200/jco.2004.01.178.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantCombined Modality TherapyConfidence IntervalsDose Fractionation, RadiationDose-Response Relationship, RadiationHumansLung NeoplasmsNeoplasm StagingOdds RatioPneumonectomyPrognosisRadiotherapy DosageRadiotherapy, AdjuvantRandomized Controlled Trials as TopicRisk AssessmentSurvival AnalysisTreatment OutcomeConceptsThoracic radiation therapyPlatinum-based chemotherapyRisk ratioRadiation therapyLS-SCLCLung cancerLimited-stage small cell lung cancerSmall cell lung cancerHyperfractionated radiation therapyLimited-Stage SmallProphylactic cranial irradiationCombined modality therapyCell lung cancerCranial irradiationChemotherapy regimensChemotherapeutic regimenModality therapySurvival benefitRandomized trialsDaily fractionationSubset analysisRadiation fractionationRT relativeRisk differenceChemotherapyThymic tumors
Detterbeck FC, Parsons AM. Thymic tumors. The Annals Of Thoracic Surgery 2004, 77: 1860-1869. PMID: 15111216, DOI: 10.1016/j.athoracsur.2003.10.001.Peer-Reviewed Original ResearchConceptsComplete resectionThymic tumorsMainstay of treatmentSurvival of patientsIVA thymomaPostoperative radiotherapyThymic carcinomaPreoperative chemotherapyIndolent coursePartial resectionStage IIIResectionThymomaPatientsAggressive behaviorTumorsLittle benefitSuch casesChemotherapyCarcinomaRadiotherapyMainstay